We examined whether AQP4 genetic variation was associated with AD pathology or modified the association between sleep duration and AD biomarkers.<h4>Methods</h4>A total of 450 dementia-free participants (mean age = 58 ± 9.9; women = 54%) from the Framingham Heart Study (FHS) with sleep duration measured by self-report and amyloid-β (Aβ) and tau burden quantified using positron emission tomography (PET) were analyzed.<h4>Results</h4>AQP4 was not associated with Aβ or tau burden in the overall sample. This evidence concerns the gene MAPT and Alzheimer disease.